LNC Therapeutics Group

With a Doctorate of Pharmacy and a qualification from a business school, Jean-Luc started his career in 1995 with SmithKline-Beecham (subsequently GSK) before joining Aventis Pharma (subsequently Sanofi) to work in a variety of industrial and financial roles based in Europe, Asia and Africa (Vietnam, Senegal, Maroc).

Fascinated by the field of nutrition, and convinced of its added value in the global management of patients, for the past ten years Jean-Luc has been focusing on the convergence between nutrition and pharmaceuticals in the context of the changing business model for the life sciences, and has been the manager or director of several SME.

He has also acted as a consultant for European investment funds, pharmaceutical companies and firms specialised in medical nutrition.

Sandrine joined LNC  in 2017 as Chief Scientific Officer and is also Associate Professor in Integrative Metabolism in the department of Food and Nutritional Sciences at the University of Reading.

She obtained her PhD in Biochemistry at Imperial College London, where she started to study host – gut microbiota metabolic interplays. She is a key member of MyNewGut, a large EU-funded consortium investigating the role of gut microbiota on the development of obesity and associated alterations of cognition.

She acts as associate editor for the journals Microbial Ecology in Health and Disease and Scientific Data. She is elected secretary of the Society for Microbial Ecology and Disease.

Graduated from ISG Paris, Fabrice has a double competence financial management and supply chain management gained during a professional experience of 20 years, including as Senior Auditor at KPMG, then as Director, Industrial and Supply Chain in Oenobiol / Sanofi.

Convinced by the innovative approach of LNC Therapeutics project and determined to meet an entrepreneurial challenge, Fabrice joined the company from its inception.

Jean-Pierre LEHNER MD, cardiologist and internal medicine graduate served during 30 years the pharmaceutical industry. Before joining pharmaceutical industry Jean-Pierre was practitioner in Hospital Bichat, Paris (France), where during the last 4 years he was heading the Intensive Care Unit of Cardiology.

Dr. Lehner assumed various roles in medical affairs. In 1981, he joined Roussel-Uclaf Company first as medical director in France, then in charge of international clinical development untill 1992.

Dr. Lehner served successively at sanofi as Head of Clinical Development during 4 years before taking the scientific director position in France until 2002 and developed the European medical team before taking the position of Global Medical Director 2005.

Following his initial studies in economic, sociology and commerce (ESSEC), Claude starting working in the pharmaceutical industry with ROUSSEL UCLAF (subsequently HOESCHT ROUSSEL) where he stayed for 22 years (based in Argentina and Italy), in particular as International Sales and Marketing Director, CEO Italy and President Roussel France. He then returned to France as Associated Shareholder several SME : Leurquin, Proteika Nutrition and Dietic & Co.

Claude became specialised in clinical pharmacology and the study of metabolic syndrome. He took an active part in the creation of LNC Therapeutics.

Claude is also President of APRC Microbiome, a French association which organises symposia with the National Academy of Medicine on this subject.

Isabelle brings 25 years of international experience in life sciences business development and finance. She started her career in ’91 at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development.

Since ’98, she was Associate Director of Business Development at Fournier/Abbott and signed several deals in Europe and in the US. Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July 2001 to create the lifesciences department.

Isabelle leads the lifesciences team and makes direct investments, mainly  in France and Scandinvia  with a focus on biotech, nutrition, personalized medicine and especially microbiome. Isabelle’s trackrecord includes Santaris (solde to Roche for $450 millions in august 2014), argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience.

Holding a Supplementary Specialised Studies Diploma (DESS) in Clinical Psychopathology, and bilingual in English, she started her professional career by gaining clinical experience in hospitals as a neuropsychologist.

In 1992, Virginie Lleu joined the pharmaceutical company Jouveinal to work in its Human Resources Directorate. She then moved as a consultant to a recruitment agency specialised in the healthcare field, GSA, subsequently joining Pact & Partners International as Senior Consultant responsible for the Health and Biotechnologies sector.

As from 2000, Virginie pursued her work as a recruitment consultant with Executive Search International entities such as Korn Ferry International and Spencer Stuart, where she contributed to developing the Health and Biotechnologies Department.

Jean-Michel Petit heads the venture capital and seed funding activities of the IRDI Group. He is thus Director General of IRDInov, the regional seed-stage fund for south-western France. Before joining IRDI, he spent 10 years in Canada, notably working in the venture capital branch of the Caisse de Dépôt du Québec where he participated actively in investing in companies and venture capital funds in both Canada and the USA and Europe.
IRDI is based in Toulouse, and has been present throughout the Aquitaine and Midi-Pyrénées for more than thirty years. Its investments target industrial companies and/or innovative enterprises at different stages of their development. The IRDI team manages funds worth more than €125 billion via the IRDI, MPC, IRDInov, FAM and SOCRI vehicles.